Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
10Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
BioXcel Therapeutics, Inc. (BTAI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
19Total relationships
4Distinct source URLs
10High confidence
0.773Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
BioXcel Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
APTUIT-OXFORD-LTD
APTUIT-OXFORD-LTD
92%
Drug substance is produced by Aptuit (Oxford) Ltd, an Evotec Company, and drug product by Pharma Services (Patheon) by Thermo Fisher Scientific
BIOXCEL-LLC
BIOXCEL-LLC
92%
We continue to depend on BioXcel LLC to provide us with certain services for our business.
RODMAN-RENSHAW-LLC
RODMAN-RENSHAW-LLC
92%
The Company agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds from the Offering, and issue to the Placement Agent or its designees warrants to purchase a number of shar…
CANACCORD-GENUITY-LLC
CANACCORD-GENUITY-LLC
90%
including our initial public offering, private placements of our common stock, registered offerings of our common stock, an Equity Distribution Agreement with Canaccord Genuity LLC ("Canaccord"), and…
Reciprocal relationship from OCSL graph: olidated Statements of Cash Flows (in thousands) (unaudited) Six months ended March 31, 2026 Six months ended March 31, 2025 Operating activities: Net increas…
Reciprocal relationship from TLX graph: her strengthens our supply chain, reducing environmental impact while maximizing resource utilization. We recognize that the future of isotope supply lies in o…
BioXcel Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
GPOS
GPOS
85%
During the fourth quarter of 2022, we began contracting directly with intermediaries such as GPOs.
Reciprocal relationship from TMO graph: Reciprocal relationship from BTAI graph: Reciprocal relationship from TMO graph: Reciprocal relationship from BTAI graph: Reciprocal relationship from TMO grap…
lization of our products or to produce our products in accordance with cGMP prescribed by the FDA or similar foreign requirements. Drug manufacturing facilities are subject to inspection before the F…
ARX-LLC
ARX-LLC
62%
d December 31, 2025 and 2024 Product Revenue, Net 121 Table of Contents Commercial sales of IGALMI ® launched in July 2022. As part of the Company’s Reprioritization, the IGALMI ® commercial team shi…
BIOXCEL-LLC-BIOXCEL-LLC
BIOXCEL-LLC-BIOXCEL-LLC
62%
n us and BioXcel LLC. BioXcel LLC may experience challenges with the acquisition, development, enhancement, or deployment of technology necessary for EvolverAI. We may face similar challenges with ot…
CANACCORD-GENUITY-LLC
CANACCORD-GENUITY-LLC
62%
impact on our liquidity and future funding requirements are uncertain as of the filing date of this Annual Report on Form 10-K. We will need substantial additional funding, and if we are unable to ra…
DERIVATIVE-LIABILITY-ARMISTICE-CAPITAL-MASTER-FU
DERIVATIVE-LIABILITY-ARMISTICE-CAPITAL-MASTER-FU
62%
e will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85 % of the fair value of a share on the first trading day or on the last …
DERIVATIVE-LIABILITY-INTRACOASTAL-CAPITAL-LLC
DERIVATIVE-LIABILITY-INTRACOASTAL-CAPITAL-LLC
62%
e will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85 % of the fair value of a share on the first trading day or on the last …
EQUITY-ARMISTICE-CAPITAL-MASTER-FUND-LTD
EQUITY-ARMISTICE-CAPITAL-MASTER-FUND-LTD
62%
e will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85 % of the fair value of a share on the first trading day or on the last …
LEARNING-RESOURCES-INC
LEARNING-RESOURCES-INC
62%
I® is listed in the Orange Book and is not currently a generic, biosimilar, or orphan drug, we may be subject to these duties to the extent any portion of IGALMI® or its active pharmaceutical ingredi…
BioXcel Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BTAI-DEBT-8391
Warrants outstanding: 8620000
90%
xbrl warrant detail from xbrl 2025-12-31.
BTAI-DEBT
Debt stack $104.5M
90%
Market cache reports total debt of $104.5M.
BioXcel Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioXcel Therapeutics, Inc..
BioXcel Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
BTAI-OWNER-MILLENNIUM-MANAGEMENT-LLC
MILLENNIUM MANAGEMENT LLC
90%
13F overlay lists MILLENNIUM MANAGEMENT LLC as top holder; 41 tracked holders.
BioXcel Therapeutics, Inc. Extended Supply Chain Network
